top of page

Company Profile

We are a drug discovery bio-venture originated from Asahikawa Medical University, established based on the research of Professor Mikihiro Fujiya’s group, Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Department of Medicine, Asahikawa Medical University.

We were founded in April 2018 after inheriting research from Asahikawa Medical University and Sapporo Holdings Co., Ltd. on the "development of novel therapeutic agents for inflammatory bowel disease using probiotic-derived long-chain polyphosphoric acid".

We are conducting research and development of candidate substances for new therapeutic agents utilizing probiotic-derived bioactive substances in the gastrointestinal and anticancer fields.

Company name

Kamui Pharma, Inc.

Head Office Location

Asahikawa Medical University, 2-1-1-1, Midorigaoka-Higashi, Asahikawa,
078-8510 JAPAN

Company establishment date

4/2, 2018

Business content

Pharmaceuticalization of bioactive substances derived from probiotics (effective microorganisms)

Board member

CEO

Naoki OGAWA(Associate Professor of Intellectual Property Center,                                        Asahikawa Medical University)

CSO 

Mikihiro FUJIYA(Proffessor of Division of Metabolism and Biosystemic Science,                                                 Gastroenterology, and Hematology/Oncology, Department of Medicine,    

                             Asahikawa Medical University

Director

Hiroyuki HASEGAWA(Operating Officer of Mitsubishi UFJ Capital Co., Ltd.)

Accounting adviser

Kenji MAEKAWA(Representative of MAEKAWA CPA Office)

bottom of page